Stock News

Revance Therapeutics, Inc. (RVNC) Analysts See $-0.97 EPS; Last Week Analogic (ALOG) Analysts

Analysts expect Revance Therapeutics, Inc. (NASDAQ:RVNC) to report $-0.97 EPS on February, 26.They anticipate $0.02 EPS change or 2.11% from last quarter’s $-0.95 EPS. After having $-1.01 EPS previously, Revance Therapeutics, Inc.’s analysts see -3.96% EPS growth. The stock increased 1.82% or $0.55 during the last trading session, reaching $30.75. About 172,766 shares traded. Revance Therapeutics, Inc. (NASDAQ:RVNC) has risen 20.40% since February 14, 2017 and is uptrending. It has outperformed by 3.70% the S&P500.

Among 4 analysts covering Analogic Company (NASDAQ:ALOG), 1 have Buy rating, 0 Sell and 3 Hold. Therefore 25% are positive. Analogic Company had 7 analyst reports since November 23, 2015 according to SRatingsIntel. The rating was maintained by Jefferies with “Hold” on Wednesday, December 6. The firm has “Buy” rating by Brean Capital given on Thursday, September 22. On Wednesday, August 9 the stock rating was initiated by Jefferies with “Hold”. The company was maintained on Wednesday, September 20 by Jefferies. The stock of Analogic Corporation (NASDAQ:ALOG) earned “Hold” rating by Benchmark on Wednesday, December 7. The stock of Analogic Corporation (NASDAQ:ALOG) has “Neutral” rating given on Thursday, March 24 by Sidoti. See Analogic Corporation (NASDAQ:ALOG) latest ratings:

06/12/2017 Broker: Jefferies Rating: Hold New Target: $80.0 Maintain
20/09/2017 Broker: Jefferies Rating: Hold New Target: $75.0 Maintain

Among 11 analysts covering Revance Therapeutics (NASDAQ:RVNC), 9 have Buy rating, 0 Sell and 2 Hold. Therefore 82% are positive. Revance Therapeutics had 24 analyst reports since August 22, 2015 according to SRatingsIntel. The stock of Revance Therapeutics, Inc. (NASDAQ:RVNC) has “Buy” rating given on Thursday, July 20 by Cantor Fitzgerald. The stock has “Buy” rating by Cowen & Co on Wednesday, January 17. The rating was maintained by Mizuho on Wednesday, December 6 with “Buy”. The rating was maintained by Aegis Capital with “Buy” on Thursday, June 8. The firm has “Buy” rating given on Thursday, November 16 by Mizuho. The stock of Revance Therapeutics, Inc. (NASDAQ:RVNC) has “Buy” rating given on Thursday, November 2 by SunTrust. Cantor Fitzgerald maintained Revance Therapeutics, Inc. (NASDAQ:RVNC) on Wednesday, December 13 with “Buy” rating. The company was maintained on Friday, December 8 by SunTrust. Aegis Capital initiated Revance Therapeutics, Inc. (NASDAQ:RVNC) rating on Tuesday, November 29. Aegis Capital has “Buy” rating and $28 target. The company was initiated on Tuesday, December 5 by Guggenheim.

Since August 23, 2017, it had 0 insider purchases, and 4 sales for $1.20 million activity. $179,185 worth of stock was sold by Browne L Daniel on Wednesday, September 20. SILVERNAIL LAUREN P sold $297,760 worth of stock or 11,164 shares.

Investors sentiment decreased to 1 in 2017 Q3. Its down 0.96, from 1.96 in 2017Q2. It worsened, as 12 investors sold Revance Therapeutics, Inc. shares while 25 reduced holdings. 8 funds opened positions while 29 raised stakes. 27.21 million shares or 0.30% less from 27.29 million shares in 2017Q2 were reported. Renaissance Techs Ltd Co owns 0% invested in Revance Therapeutics, Inc. (NASDAQ:RVNC) for 79,792 shares. Voya Investment Limited Liability Corporation holds 0% or 10,392 shares. Sg Americas Securities Ltd Com holds 0% in Revance Therapeutics, Inc. (NASDAQ:RVNC) or 5,231 shares. First Personal Svcs holds 808 shares or 0% of its portfolio. 53,008 were reported by Rothschild Asset Mgmt. California State Teachers Retirement owns 0% invested in Revance Therapeutics, Inc. (NASDAQ:RVNC) for 36,522 shares. Suffolk Capital Mngmt Ltd Llc stated it has 53,097 shares or 0.19% of all its holdings. Rhumbline Advisers stated it has 25,603 shares or 0% of all its holdings. Jpmorgan Chase And owns 3.55M shares or 0.02% of their US portfolio. Tower Rech Capital Limited Liability (Trc) reported 3,150 shares. 2.01 million are held by National Bank & Trust Of Ny Mellon. Zurcher Kantonalbank (Zurich Cantonalbank) has invested 0% in Revance Therapeutics, Inc. (NASDAQ:RVNC). 2.17 million were reported by Blackrock. State Common Retirement Fund owns 23,300 shares for 0% of their portfolio. Ameriprise Fincl invested 0% in Revance Therapeutics, Inc. (NASDAQ:RVNC).

Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacturing, and commercialization of novel botulinum toxin products for various aesthetic and therapeutic indications. The company has market cap of $1.12 billion. The company's lead drug candidate is DaxibotulinumtoxinA for injection , which is in Phase III clinical trials to treat glabellar (frown) lines, as well as in Phase II clinical trials for the treatment of cervical dystonia and plantar fasciitis. It currently has negative earnings. It is also developing DaxibotulinumtoxinA topical gel (RT001) that is in preclinical development.

Investors sentiment decreased to 0.91 in Q3 2017. Its down 0.53, from 1.44 in 2017Q2. It is negative, as 16 investors sold Analogic Corporation shares while 52 reduced holdings. 15 funds opened positions while 47 raised stakes. 11.72 million shares or 4.37% less from 12.26 million shares in 2017Q2 were reported. Manufacturers Life Insur The owns 9,598 shares or 0% of their US portfolio. Art Advisors Limited Liability Corporation holds 6,260 shares. 38,699 were reported by Deutsche Bancorporation Ag. M&T National Bank Corporation accumulated 6,698 shares or 0% of the stock. Price T Rowe Associate Md holds 0.01% or 510,371 shares. Pnc Financial Services Inc has 1,150 shares for 0% of their portfolio. First Bank Of Omaha accumulated 13,835 shares or 0.07% of the stock. Thrivent For Lutherans, a Minnesota-based fund reported 7,600 shares. The New York-based New York State Common Retirement Fund has invested 0% in Analogic Corporation (NASDAQ:ALOG). Ironwood Management Limited reported 0.82% stake. Heartland Advsr Inc has invested 0.76% in Analogic Corporation (NASDAQ:ALOG). Stoneridge Investment Ptnrs Ltd Liability holds 0.07% of its portfolio in Analogic Corporation (NASDAQ:ALOG) for 5,636 shares. Millennium Mngmt Limited Liability Co stated it has 0.01% in Analogic Corporation (NASDAQ:ALOG). Citadel Advsrs Limited Co reported 103,079 shares. Texas Permanent School Fund has invested 0.01% in Analogic Corporation (NASDAQ:ALOG).

The stock decreased 0.81% or $0.65 during the last trading session, reaching $79.6. About 63,953 shares traded. Analogic Corporation (NASDAQ:ALOG) has declined 8.54% since February 14, 2017 and is downtrending. It has underperformed by 25.24% the S&P500.

Analogic Corporation designs, manufactures, and sells medical imaging systems, ultrasound and security systems, and subsystems to original equipment manufacturers and end users primarily for the medical and airport security markets worldwide. The company has market cap of $993.78 million. It operates in three divisions: Medical Imaging, Ultrasound, and Security and Detection. It currently has negative earnings. The Medical Imaging segment offers computed tomography (CT) detector systems, data acquisition systems, data management systems, and integrated CT systems; magnetic resonance imaging products, including gradient and radio frequency amplifiers; and digital mammography products, such as detector plates, as well as motion control devices for use in computer-controlled automation systems primarily for the semiconductor, food and beverage, and laboratory automation markets.

Leave a Reply

Your email address will not be published. Required fields are marked *